[Value of CT-guided biopsy in malignant lymphoma].
Management of diagnosing malignant lymphomas has changed with development of CT-guided techniques and reliable biopsy tools. Pathologists can use representative tissue samples for sub classification in more than 90%. Evaluation of residual lymphoma or relapse can be nearly as effective. Therefore percutaneous biopsy can be considered as primary diagnostic tool in the absence of peripheral lymphadenopathy. CT-guided biopsies can be performed on an outpatient basis under conscious sedation considering contraindications as well as regional complications. Acceptance of percutaneous biopsy by the pathologist and oncologist is based on diagnostic effectiveness that is significantly improved if more than 3 dagger solid tissue samples are taken. This article reviews the value of CT-guided biopsy in comparison to surgical procedures in patients with malignant lymphoma. Essential aspects that lead to a diagnostic percutaneous biopsy are discussed on grounds of the current literature.
Libicher
M
M
Abteilung Radiodiagnostik, Universitätsklinikum Heidelberg. martin.libicher@urz.uni-heidelberg.de
Nöldge
G
G
Radeleff
B
B
Gholipur
F
F
Richter
G M
GM
D000556:Ambulatory Surgical Procedures; D001707:Biopsy, Needle / Q000295:instrumentation*; D016292:Procedural Sedation; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008223:Lymphoma / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000473:pathology; D012680:Sensitivity and Specificity; D025321:Surgery, Computer-Assisted / Q000295:instrumentation*; D014057:Tomography, X-Ray Computed / Q000295:instrumentation*